Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 6, November-December, p. 877–884

Publication type: original article

Language: English

Effect of Different Bacillus Calmette-Guerin Substrains on Growth Inhibition of T24 Bladder Cancer Cells and Cytokines Secretion by BCG Activated Peripheral Blood Mononuclear Cells of PBMCs

Wiesława Janaszek-Seydlitz1,A,C,D, Marta Prygiel1,B,C, Bożena Bucholc1,E,F, Aldona Wiatrzyk1,B,C, Urszula Czajka1,B,C, Paulina Górska1,E, Urszula Soliwoda1,B

1 Department of Sera and Vaccines Evaluation, National Institute of Public Health – National Institute of Hygiene, Warszawa, Poland

Abstract

Background. Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75–85% of patients present non-muscle invasive bladder cancer (NMIBC). Standard primary treatment for NIMBC is transurethral resection (TUR) followed by intravesical Bacillus Calmette-Guerin (BCG) immunotherapy. BCG has been accepted as the most effective agent in clinical use against NMIBC. Various BCG substrains are used worldwide for bladder cancer immunotherapy although the impact of used BCG substrain on BCG antitumor capacity is a little investigated.
Objectives. The aim of this study was to compare the antitumor capacity and the ability to trigger cytokines production of three BCG substrains by stimulation of the local innate immunity in vitro.
Material and Methods. The human bladder cancer cell line T24 was co-cultured with each of the BCG substrains: Moreau, Tice and RIVM alone or with BCG pretreated DCs (dendric cells) and allogenic PBMCs derived from the same donor. The inhibition of T24 cell growth was evaluated by 3H-thymidine incorporation. Production of Th1 cytokines (IFN-γ, TNF-α, IL-12) and Th2 cytokines (IL-10, IL-4) was measured in cultures of BCG–activated PBMCs by ELISA test.
Results. An approximately two-fold inhibition of T24 cell proliferation was observed as a direct cytotoxic effect of tested BCG substrains on T24 cells. However, BCG inhibited the growth of tumor cells mainly by activating the effector cells of innate immunity. About a 10-fold inhibition of T24 cell proliferation was observed when T24 cells were co-cultured with allogenic BCG pretreated DCs and PBMCs derived from the same donor. The PBMCs activated by compared live BCG substrains secreted large amounts of TNF-α and IFN-γ cytokines.
Conclusion. Tested BCG substrains had little direct inhibitory effect on T24 cell proliferation. Moreau evolutionarily early BCG substrain showed similar strong, indirect antitumor effects as evolutionarily late BCG substrains Tice and RIVM.

Key words

immunotherapy, BCG, bladder cancer, innate immunity.

References (30)

  1. Anastasiadis A, Reijke T: Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012, 4, 13–32.
  2. Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusfarques-Saklani H, Lemaitre F: Preexisting BCG-specific T cells improve intravesical immunotherapy for dladder cancer. Sci Transl Med 2012, 6, 4, 137ra72.
  3. Daher C. Chade, Shahrokh F. Shariat, Guido Dalbagni: Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. Int Braz J Urol 2009, 35, 640–651.
  4. Shelley MD, Mason MD, Kynaston H: Intravesical therapy for superficial bladder cancer: a systematic review of randomized trials and meta-analyses. Cancer Treat Rev 2010, 36, 195–205. Epub 2010 Jan 15.
  5. Morales A, Eidinger D, Bruce AW: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976, 116, 180–183.
  6. Luo Y, Chen A, O’Donnell MA: Role of Th1 and Th2 cytokines in BCG – induced IFN-γ production cytokine promotion and simulation of BCG effect. Cytokine 2013, 21, 17–26.
  7. Kavoussi L, Brown E, Ritchey J, Ratliff T: Fibronectin-mediated Calmette-Guerin Bacillus attachment to murine bladder mucosa. J Clin Invest 1990, 85, 62–67.
  8. Higuchi T, Shimizu M, Owaki A, Takahashi M, Skinya E, Nashimura T: A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for inhibition of tumor growth. Cancer Immunol Immunother 2009, 58, 1245–1255.
  9. Rajala P, Kaasinen E, Rintala, Jauhiainen K, Nurmi M, Alfhan O: Cytostatic effect of different strains of Bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon alpha. Urol Res 1992, 20, 215–217.
  10. Schwarzer K, Foerster M, Steiner T, Hermann IM, Straube E: BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis. Cancer Cell Int 2010, 10, 21.
  11. Secanella-Fandos S, Luquin M, Julian E: Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guerin substrains. J Urol 2013, 189, 711–718.
  12. Hynes R, Yamada K: Fibronectins: multifunctional modular glycolprotein. J Cell Biol 1982, 95, 369–377.
  13. Click E, Balian G: Domain structure of human plasma and cellular fibronectin: use of a monoclonal antibody and heparin affinity t identify three different subunit chains. Biochemistry 1985, 24, 6685–6696.
  14. Azlanzadeh J. Brown J, Quillin S, Ritchey JK, Ratliff TL: Characterization of soluble fibronectin binding to BCG. J Gen Microbiol 1989, 135, 2735–2741.
  15. Askeland E, Newton M, O’Donnell M, Luo Y: Bladder cancer immunotheraphy: BCG and Beyond. Adv Urol 2012, ID, 181987, 13.
  16. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE: A retrospective analysis of 153 patients treated with or without intravesical Bacillus Calmette-Guerin for primary stage T1 grade bladder cancer: recurrence, progression and survival. J Urol 2003, 169, 96–100.
  17. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF: Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992, 147, 1636–1642.
  18. Saint F, Patard JJ, Groux Muscatelli B, Lefrere Belde MA, Gil Diez de Medina S, Abbou CC: Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after Bacillus Calmette-Guerin treatment. BJU Int 2001, 88, 602–610.
  19. Bohle A, Brandau S: Immune mechanisns in Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003, 170, 964–969.
  20. De Boer EC, De Jong WH, Van Der Meijden AP, Steerenberg PA, Witjes JA, Veqt PD: Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with Bacillus Calmette-Guerin. Cancer Immunol Immunother 1991, 33, 411–416.
  21. De Boer EC, De Jong WH, Van Der Meijden AP, Steerenberg PA, Witjes F, Veqt PD: Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometrical analysis. Urol Res 1991, 19, 45–50.
  22. Luo Y, Chen X, O’Donnell MA: Mycobacterium bovis Bacillus Calmette-Guerin (BCG) induces human CCand CXC-chemokines in vitro and in vivo. Clin Exp Immunol 2007, 147, 370–378.
  23. O’Donnell M, Chen X, Szilvasi A, Hunter S, Clinton S: Role of IL-12 in the induction and potentiation of IFN-γ in the response to Bacillus Calmette-Guerin. J Immunol 1999, 163, 4246–4252.
  24. Papageorgiou A, Lashinger L, Milikan R: Role of tumor necrosis factor-related apoptosis inducing ligand in interferon induced apoptosis in human bladder cancer cells. Cancer Res 2004, 64, 8973–8979.
  25. Luo X, Han R, Evanoff D, Chen X: Interleukin-10 inhibits Mycobacterium bovis Bacillus Calmette-Guerin (BCG)- induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol 2010, 160, 359–368.
  26. Agarwal A, Agarwal U, Verma S, Mohanty NK, Saxena S: Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre and post-intravesical combination immunotherapy. Immunopharmacol Immunotoxicol 2010, 32, 348–356.
  27. Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L: Prognostic value of a T helper 1 urinary cytokine response after intravesical Bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002, 167, 364–367.
  28. Sanchez-Carbayo M, Urrutia M, Romani R, Herreo M, Gonzalez de Buitrago JM, Navajo JA: Serial urinary IL-2, IL-6, IL-8, TNF-alpha, UBC, CYDRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravisical BCG. Anticancer Res 2001, 21, 3041–3047.
  29. Cairo C, Hebbeler AM, Propp N, Bryant JL, Colizzi V, Pauza CD: Innate-like gammadelta T cell responses to mycobacterium Bacilli Calmette-Guerin using the public V gamma 2 repertoire in Macaca fascicularis. Tuberculosis 2007, 87, 373–383.
  30. O’Toole CM, Povey S, Hepburn P, Franks LM: Identity of some human bladder cancer cell lines. Nature 1983, 301, 429–430.
© Wroclaw Medical University